Advertisement
Genomma Lab expects net sales growth in the range of 42% to 45% for thefull year of 2010, excluding possible acquisitions, and an EBITDA marginbetween 25.0% and 26.0%, from 2009 year-end results which we expect to beabove our last issued guidance.
Advertisement
The Company's estimates are based on organic growth in base line products,the full year effect in sales of products launched or acquired during 2009,growth in international operations as well as product line extensions and newbrands in existing and new categories.
Company Description
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growingpharmaceutical and personal care products companies in Latin America. GenommaLab develops, sells and markets a broad range of premium branded products,many of which are leaders in the categories in which they compete in terms ofsales and market share. The Company has a sound business model through aunique combination of a new product development process, consumer orientedmarketing, a broad retail distribution network and a low-cost, highly flexiblesupply chain operating model.Contact: Oscar Villalobos Tel: +52 (55) 5081- 0000 ext. 4250 E-mail: [email protected] In New York: i-advize Corporate Communications, Inc. Tel: (212) 406-3695 E-mail: [email protected]
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
